Literature DB >> 24355418

Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer.

Guru Sonpavde1, Matthew D Galsky2, David Latini3, Guoqing J Chen3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24355418     DOI： 10.1016/j.clgc.2013.11.016

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  12 in total

Review 1.  Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.

Authors:  David J Einstein; Guru Sonpavde
Journal:  Curr Treat Options Oncol       Date:  2019-02-11

Review 2.  Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition.

Authors:  Arlene Siefker-Radtke; Brendan Curti
Journal:  Nat Rev Urol       Date:  2017-12-05       Impact factor: 14.432

Review 3.  Management of Advanced Urothelial Carcinoma in Older and Frail Patients: Have Novel Treatment Approaches Improved Their Care?

Authors:  Brian M Russell; Leora Boussi; Joaquim Bellmunt
Journal:  Drugs Aging       Date:  2022-03-28       Impact factor: 4.271

4.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Authors:  Arjun V Balar; Matthew D Galsky; Jonathan E Rosenberg; Thomas Powles; Daniel P Petrylak; Joaquim Bellmunt; Yohann Loriot; Andrea Necchi; Jean Hoffman-Censits; Jose Luis Perez-Gracia; Nancy A Dawson; Michiel S van der Heijden; Robert Dreicer; Sandy Srinivas; Margitta M Retz; Richard W Joseph; Alexandra Drakaki; Ulka N Vaishampayan; Srikala S Sridhar; David I Quinn; Ignacio Durán; David R Shaffer; Bernhard J Eigl; Petros D Grivas; Evan Y Yu; Shi Li; Edward E Kadel; Zachary Boyd; Richard Bourgon; Priti S Hegde; Sanjeev Mariathasan; AnnChristine Thåström; Oyewale O Abidoye; Gregg D Fine; Dean F Bajorin
Journal:  Lancet       Date:  2016-12-08       Impact factor: 79.321

Review 5.  [Immunotherapy for locally advanced and metastasized bladder cancer].

Authors:  W Loidl; F Luger
Journal:  Urologe A       Date:  2018-11       Impact factor: 0.639

Review 6.  Bladder cancer in the elderly patient: challenges and solutions.

Authors:  Elizabeth A Guancial; Breton Roussel; Derek P Bergsma; Kevin C Bylund; Deepak Sahasrabudhe; Edward Messing; Supriya G Mohile; Chunkit Fung
Journal:  Clin Interv Aging       Date:  2015-06-10       Impact factor: 4.458

7.  Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma.

Authors:  Yang-Min Ning; V Ellen Maher; Julia A Beaver; Kirsten B Goldberg; Gideon M Blumenthal; Richard Pazdur
Journal:  Oncologist       Date:  2017-11-27

8.  Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States.

Authors:  Matthew D Galsky; Sumanta Kumar Pal; Shih-Wen Lin; Sarika Ogale; Marko Zivkovic; Joseph Simpson; Christina Derleth; Christina Schiff; Guru Sonpavde
Journal:  Bladder Cancer       Date:  2018-04-26

9.  Dramatic Responses of Recurrent Upper Urinary Tract Urothelial Carcinoma Harboring FGFR3 and TP53 Activating Mutations to Pembrolizumab in Combination with Erdafitinib: A Case Report.

Authors:  Xinjia Ding; Jianguo Zong; Xiang Li; Xiaoyan Bai; Bowen Tan; Weibing Sun; Ruoyu Wang; Yan Ding
Journal:  Onco Targets Ther       Date:  2021-03-25       Impact factor: 4.147

Review 10.  Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience.

Authors:  Michael Crist; Gopa Iyer; Miles Hsu; William C Huang; Arjun V Balar
Journal:  Ther Adv Urol       Date:  2019-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.